Immunogen (IMGN) has released an update.
ImmunoGen, Inc. is set to become a subsidiary of AbbVie Inc. following a merger agreement between the two companies, with ImmunoGen surviving the merger. The completion of this strategic move hinges on antitrust regulatory approval, which seems promising as the mandatory waiting period under the HSR Act has passed without objection from the Federal Trade Commission. The anticipated finalization date for this transaction is on or around February 12, 2024, marking a significant event for both entities in the biopharmaceutical industry.
For further insights into IMGN stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
